NCT06028490

A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.

The Efficacy and Safety of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Conventional Treatment: A Randomized, Double-Blind, Placebo-controlled Investigator Initiated Trial.

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Zheng Liu ENT · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

Conditions

• Allergic Rhinitis

Interventions

Type	Name	Description
BIOLOGICAL	GR1802 injection-1	subcutaneous，dose\*1
BIOLOGICAL	GR1802 injection-2	subcutaneous，dose\*2
BIOLOGICAL	Placebo	subcutaneous，dose\*2

Timeline

• Start date: 2023-09-07
• Primary completion: 2023-11-01
• Completion: 2023-11-01
• First posted: 2023-09-08
• Last updated: 2023-09-11

Locations

1 site across 1 country: China